Kuehn Law, PLLC

Kuehn Law, PLLC is a legal firm specializing in complex contingency-fee litigation, primarily representing shareholders, professional investors, and consumers. The firm's mission centers on upholding shareholder and consumer rights through legal action. Headquartered at 53 Hill Street, Suite 605, Southampton, NY 11968, Kuehn Law focuses on accountability for companies and their leadership.

The firm's core services include Shareholder Derivative Litigation, Merger Litigation, Shareholder Class Actions, and Consumer Class Actions. These practice areas involve pursuing legal remedies for clients impacted by corporate misconduct, breaches of fiduciary duty, and other complex financial disputes.

Founded by Justin A. Kuehn at the end of 2023, Kuehn Law has quickly established an active presence in shareholder litigation. Mr. Kuehn, an attorney with expertise in securities and consumer class actions, leads the firm. Recent activities include investigations into potential breaches of fiduciary duties by officers and directors of publicly traded companies such as Fermi Inc., Vistagen Therapeutics, Inc., F5, Inc., and Driven Brands Holdings Inc., indicating a proactive market positioning in protecting investor interests.

Latest updates

Varonis Faces Securities Suit Over SaaS Transition Misrepresentation

Event summary

  • Kuehn Law, PLLC is investigating Varonis Systems, Inc. (VRNS) officers and directors for potential breach of fiduciary duties.
  • A federal securities lawsuit alleges Varonis misrepresented its ability to convert existing customers to a SaaS offering.
  • The lawsuit claims Varonis failed to disclose its inability to retain customers during the SaaS transition, impacting ARR growth.
  • The investigation is focused on shareholders who purchased VRNS stock prior to February 4, 2025.

The big picture

This lawsuit highlights the risks associated with transitioning legacy software businesses to a SaaS model, particularly when customer retention proves challenging. The allegations suggest a potential failure in Varonis’s execution of its SaaS strategy and a lack of transparency with investors regarding the challenges involved. The case could set a precedent for increased scrutiny of companies undergoing similar transitions and the accuracy of their projections.

What we're watching

Financial Exposure
The potential financial impact of the lawsuit on Varonis will depend on the extent of the misrepresentation and the resulting legal costs and settlements.
SaaS Adoption
Varonis’s ability to successfully transition its remaining on-premise customers to a SaaS model will be critical for future revenue growth and will be closely scrutinized.
Management Scrutiny
The board’s oversight of management’s SaaS transition strategy and its communication with investors will be under increased scrutiny, potentially leading to governance changes.

Fermi Inc. Faces Shareholder Lawsuit Over Project Matador Funding

Event summary

  • Kuehn Law is investigating Fermi Inc. (FRMI) officers and directors for potential breaches of fiduciary duty.
  • The lawsuit alleges Fermi misrepresented tenant demand and funding risks associated with the Project Matador campus.
  • The alleged misrepresentations occurred prior to October 1, 2025.
  • Shareholders who purchased FRMI stock before October 1, 2025, are being encouraged to contact Kuehn Law.

The big picture

This lawsuit highlights the growing trend of shareholder litigation targeting companies with opaque financial disclosures and high-risk development projects. The Project Matador situation underscores the dangers of relying on single-tenant funding commitments in large-scale real estate ventures, a practice increasingly common as construction financing tightens. The allegations, if proven, could trigger a broader reassessment of Fermi's governance and risk management practices.

What we're watching

Litigation Risk
The outcome of the shareholder lawsuit will significantly impact Fermi's financial outlook and potentially trigger further scrutiny of its Project Matador development strategy.
Funding Stability
The reliance on a single tenant’s funding commitment for Project Matador exposes Fermi to considerable risk, and the firm's ability to secure alternative financing will be critical.
Disclosure Practices
Fermi’s disclosure practices regarding Project Matador and its financial dependencies will be under increased scrutiny, potentially leading to changes in reporting protocols.

Snap Lawsuit Alleges Misrepresentation of Advertising Revenue Growth

Event summary

  • Kuehn Law, PLLC is investigating Snap, Inc. officers and directors for potential breach of fiduciary duties.
  • A federal securities lawsuit alleges Snap misrepresented advertising revenue growth, with rates declining from 9% to 1% between Q1 and April 2026.
  • The investigation focuses on actions taken prior to April 29, 2025.
  • Kuehn Law is covering all case costs for potential SNAP shareholders who contact the firm.

The big picture

The lawsuit highlights growing investor skepticism regarding the accuracy of advertising revenue growth claims within the social media landscape. Snap's declining growth rate, coupled with allegations of misrepresentation, underscores the challenges of maintaining user engagement and ad revenue in a maturing market. This case could set a precedent for increased shareholder activism and legal challenges against companies facing similar revenue deceleration.

What we're watching

Governance Dynamics
The outcome of this lawsuit will likely influence Snap's board oversight and executive compensation structures, potentially leading to increased scrutiny of financial reporting practices.
Regulatory Headwinds
This case could embolden further regulatory action regarding transparency in advertising revenue metrics across the social media sector, particularly concerning execution failures.
Execution Risk
Snap's ability to regain investor confidence will depend on demonstrating a clear and sustainable plan to improve advertising revenue growth and restore trust in its financial disclosures.

Nutex Health Faces Shareholder Lawsuit Over HaloMD Arbitration Scheme

Event summary

  • Kuehn Law is investigating Nutex Health (NUTX) officers and directors for potential breach of fiduciary duties.
  • The investigation stems from a federal securities lawsuit alleging misrepresentation and failure to disclose a scheme involving HaloMD to defraud insurance companies.
  • The lawsuit claims Nutex overstated remediation of internal control weaknesses and improperly classified stock-based compensation.
  • The alleged misconduct occurred prior to August 8, 2024, and impacts shareholders who purchased NUTX shares before that date.

The big picture

This lawsuit highlights the increasing scrutiny of third-party relationships and arbitration practices within the healthcare technology sector. The allegations of fraudulent activity and misrepresentation of financial data underscore the importance of robust internal controls and transparent disclosures, particularly for companies relying on complex revenue models. The timing of the lawsuit, following a period of heightened regulatory focus on healthcare billing and compliance, suggests a broader trend of increased accountability for industry participants.

What we're watching

Legal Exposure
The outcome of the shareholder lawsuit will significantly impact Nutex Health's financial standing and reputation, potentially leading to substantial settlements or penalties.
HaloMD Relationship
The future of Nutex’s relationship with HaloMD remains uncertain, and any further revelations regarding their arbitration practices could trigger additional scrutiny.
Internal Controls
Nutex will need to demonstrably strengthen its internal controls over financial reporting to regain investor confidence and avoid future SEC scrutiny.

Ramaco Resources Faces Shareholder Lawsuit Over Brook Mine Disclosures

Event summary

  • Kuehn Law, PLLC is investigating Ramaco Resources (METC) officers and directors for potential breach of fiduciary duties.
  • A federal securities lawsuit alleges Ramaco misrepresented or failed to disclose a lack of significant mining activity at the Brook Mine.
  • The lawsuit claims Ramaco overstated development progress at the Brook Mine.
  • The investigation pertains to shareholders who purchased METC stock prior to July 31, 2025.

The big picture

This lawsuit highlights the increasing pressure on resource companies to provide transparent and accurate updates on project development, particularly as investors demand greater accountability. The allegations, if proven, could set a precedent for stricter oversight of mining project disclosures and potentially impact valuations across the sector. The timing of the lawsuit, occurring after a period of heightened investor focus on ESG and operational transparency, underscores the risks associated with misleading investors about material developments.

What we're watching

Litigation Risk
The outcome of the lawsuit will likely influence investor sentiment and could lead to significant financial penalties or governance changes at Ramaco Resources.
Disclosure Practices
Increased scrutiny of Ramaco's disclosure practices is probable, potentially impacting future reporting and investor relations.
Project Execution
The viability and timeline of the Brook Mine project will be heavily scrutinized, as the lawsuit directly challenges the accuracy of prior progress reports.

Lineage Faces Shareholder Lawsuit Alleging IPO Misrepresentation

Event summary

  • Kuehn Law, PLLC is investigating Lineage, Inc. (LINE) for potential breaches of fiduciary duty by its officers and directors.
  • The lawsuit alleges Lineage misrepresented or failed to disclose that its financial and operational results were artificially inflated leading up to its IPO.
  • The alleged misrepresentation is attributed to factors including COVID-19 pandemic impacts, increased cold-storage facility supply, and unsustainable price increases.
  • The investigation is focused on shareholders who purchased LINE stock prior to August 1, 2024.

The big picture

This lawsuit highlights the ongoing risks associated with companies that experienced rapid growth during the COVID-19 pandemic and subsequently went public. The allegations suggest a potential failure to adequately disclose the temporary nature of that growth and the factors contributing to it. The case could set a precedent for increased scrutiny of IPOs and the accuracy of financial disclosures, particularly in sectors that benefited from pandemic-driven demand.

What we're watching

Legal Exposure
The outcome of the shareholder lawsuit will significantly impact Lineage’s financial outlook and potentially trigger further scrutiny of its IPO process and accounting practices.
Governance Scrutiny
The allegations will likely prompt a review of Lineage’s board oversight and internal controls, potentially leading to changes in board composition or governance structures.
Market Perception
Investor confidence in Lineage may be eroded, impacting its stock price and ability to secure future financing until the legal proceedings are resolved and the underlying issues are addressed.

iRhythm Technologies Faces Shareholder Lawsuit Over Zio AT Monitor Disclosure

Event summary

  • Kuehn Law, PLLC is investigating iRhythm Technologies (IRTC) directors and officers for potential breach of fiduciary duties.
  • The lawsuit alleges iRhythm misrepresented the Zio AT monitor as a real-time device primarily for high-risk patients.
  • The alleged misrepresentation inflated the stock price, with the lawsuit referencing a period prior to November 5, 2021.
  • Kuehn Law is seeking investors who purchased IRTC stock before November 5, 2021, and will cover all case costs.

The big picture

This lawsuit highlights the increasing scrutiny of medical device companies' marketing and disclosure practices, particularly as they relate to premium-priced, specialized devices. The allegations suggest a potential disconnect between the perceived value proposition of the Zio AT monitor and its actual application, which could have broader implications for the company's growth strategy and regulatory compliance. The timing of the lawsuit, referencing activity prior to 2021, suggests a delayed reaction to concerns that may have been simmering for some time.

What we're watching

Legal Exposure
The outcome of the shareholder lawsuit will significantly impact iRhythm's financial outlook and potentially trigger further regulatory inquiries into its marketing and sales practices.
Market Perception
Investor confidence in iRhythm’s real-time monitoring technology and its market positioning will likely be affected, potentially impacting future sales and partnerships.
Disclosure Practices
The case will likely prompt a broader review of disclosure practices within the medical device industry, particularly concerning the intended use and target patient populations for innovative monitoring technologies.

SelectQuote Faces Shareholder Lawsuit Over Medicare Plan Steering Allegations

Event summary

  • Kuehn Law, PLLC is investigating SelectQuote, Inc. (SLQT) for potential breaches of fiduciary duty by its officers and directors.
  • The investigation stems from a federal securities lawsuit alleging SelectQuote misrepresented or failed to disclose practices involving Medicare beneficiary plan selection.
  • Allegations include directing beneficiaries to insurers based on compensation rather than plan suitability, receiving illegal kickbacks, and violating the False Claims Act.
  • The lawsuit concerns stock purchases made prior to September 9, 2020.

The big picture

This lawsuit underscores the increasing regulatory pressure on companies operating within the Medicare Advantage space, where conflicts of interest and beneficiary suitability are under intense scrutiny. The allegations, if proven, could significantly damage SelectQuote’s reputation and financial performance, potentially impacting the broader insurance brokerage sector. The timing of the investigation, focused on pre-September 2020 stock purchases, suggests a possible re-evaluation of past disclosures and practices.

What we're watching

Regulatory Headwinds
The potential False Claims Act violations suggest increased scrutiny from government agencies, which could lead to significant financial penalties and operational restrictions for SelectQuote.
Governance Dynamics
The lawsuit's focus on fiduciary duty breaches highlights a potential failure of oversight by the board of directors, which could trigger calls for board restructuring and enhanced compliance programs.
Execution Risk
SelectQuote's business model, reliant on Medicare Advantage plan sales, is inherently vulnerable to changes in regulatory guidelines and beneficiary preferences, potentially impacting future growth and profitability.

CTO Realty Growth Faces Shareholder Lawsuit Over Dividend Sustainability Claims

Event summary

  • Kuehn Law, PLLC is investigating CTO Realty Growth, Inc. (CTO) for potential breaches of fiduciary duty by its officers and directors.
  • The investigation stems from a federal securities lawsuit alleging misrepresentation or failure to disclose the unsustainability of CTO’s dividends.
  • Plaintiffs claim the company used deceptive practices to inflate Adjusted Funds From Operations (AFFO) and overstate the profitability of the Ashford Lane property.
  • The lawsuit concerns shares purchased prior to February 18, 2021.
  • Kuehn Law is covering all case costs and does not charge investor clients.

The big picture

This lawsuit highlights the ongoing pressure on real estate investment trusts (REITs) to maintain transparent and sustainable financial reporting, particularly concerning metrics like AFFO. The allegations suggest a potential pattern of aggressive accounting practices aimed at artificially boosting profitability, a trend that has drawn increased regulatory attention. The case could set a precedent for similar claims against other REITs and impact investor expectations regarding dividend payouts.

What we're watching

Financial Scrutiny
Increased scrutiny of CTO’s AFFO reporting and underlying property valuations is likely, potentially impacting investor confidence and stock price.
Legal Exposure
The outcome of the shareholder lawsuit will significantly influence CTO’s legal liabilities and potentially trigger further investigations into past financial practices.
Dividend Policy
CTO will need to demonstrate the sustainability of its dividend policy to regain investor trust, potentially requiring adjustments to its operational strategy.

Ardent Health Faces Shareholder Lawsuit Over Accounting Practices

Event summary

  • Kuehn Law is investigating Ardent Health’s officers and directors for potential breach of fiduciary duties.
  • A federal securities lawsuit alleges Ardent Health misrepresented or failed to disclose issues related to accounts receivable collection practices.
  • The lawsuit claims Ardent Health’s accounts receivable framework artificially inflated reported amounts and delayed loss recognition.
  • The investigation focuses on events occurring prior to July 18, 2024.
  • Kuehn Law is soliciting ARDT shareholders who purchased shares before July 18, 2024, to contact the firm.

The big picture

This lawsuit highlights growing concerns about aggressive accounting practices within the healthcare sector, particularly regarding revenue recognition and asset valuation. The allegations suggest a potential systemic weakness in Ardent Health’s internal controls and risk management, which could set a precedent for similar litigation against other hospital operators. The lack of adequate professional malpractice liability insurance further underscores the company's risk exposure.

What we're watching

Litigation Risk
The outcome of the shareholder lawsuit will significantly impact Ardent Health’s financial performance and reputation, potentially leading to substantial legal fees and settlements.
Financial Scrutiny
Increased regulatory and investor scrutiny of Ardent Health’s accounting practices and internal controls is likely, particularly concerning accounts receivable management.
Governance Oversight
The board’s oversight of financial reporting and risk management will be under intense pressure, potentially leading to changes in board composition or committee structure.

Five9 Faces Shareholder Lawsuit Over Misleading Growth Projections

Event summary

  • Shareholder litigation firm Kuehn Law is investigating Five9's officers and directors for potential breach of fiduciary duties.
  • The lawsuit alleges Five9 misrepresented the strength of its new business, claiming it was negatively impacted by macroeconomic factors.
  • Five9 reportedly failed to disclose challenges in bookings and a lack of data supporting projected retention rate improvements.
  • The investigation concerns shares purchased before February 21, 2024.

The big picture

This lawsuit highlights the increasing scrutiny of SaaS companies' growth projections, particularly in a challenging macroeconomic environment. Investors are demanding greater transparency and accountability from management teams, and the potential for significant legal costs and reputational damage underscores the importance of accurate financial reporting and robust internal controls. The case could set a precedent for similar litigation against other companies making aggressive growth claims.

What we're watching

Legal Exposure
The outcome of the shareholder lawsuit will likely influence Five9’s legal budget and potentially impact executive compensation, depending on the findings.
Sales Execution
Five9’s ability to improve sales execution and efficiency will be critical to restoring investor confidence and achieving sustainable growth.
Transparency
Five9 will need to enhance transparency regarding its financial performance and future outlook to avoid similar allegations and regain market trust.

Agilon Health Faces Shareholder Lawsuit Over 2025 Guidance and Financial Disclosures

Event summary

  • Kuehn Law, PLLC is investigating Agilon Health, Inc. (AGL) for potential breaches of fiduciary duty by its officers and directors.
  • A federal securities lawsuit alleges that Agilon Health misrepresented or failed to disclose issues related to 2025 guidance and the impact of risk-reduction strategies.
  • The lawsuit claims the 2025 guidance was 'recklessly issued' and the positive financial impact of strategic actions was overstated.
  • The investigation is focused on shareholders who purchased AGL stock prior to February 26, 2025.

The big picture

This lawsuit highlights the increasing pressure on healthcare companies to provide accurate financial guidance and transparent disclosures, especially in a challenging economic environment. The allegations suggest a potential disconnect between internal expectations and external communications, which can erode investor trust and trigger regulatory inquiries. Shareholder litigation, while costly, often serves as a catalyst for improved corporate governance practices and enhanced accountability.

What we're watching

Legal Exposure
The outcome of the shareholder derivative litigation will likely influence Agilon Health’s legal budget and potentially impact executive compensation and insurance coverage.
Financial Scrutiny
Increased scrutiny of Agilon’s financial reporting and forecasting processes is probable, potentially leading to changes in internal controls and audit procedures.
Investor Confidence
The lawsuit’s progression will likely affect investor sentiment and stock valuation, particularly among institutional holders sensitive to governance risks.

F5 Faces Shareholder Lawsuit Over Alleged Cybersecurity Misrepresentations

Event summary

  • Kuehn Law, PLLC is investigating F5, Inc. (FFIV) officers and directors for potential breach of fiduciary duties.
  • A federal securities lawsuit alleges F5 misrepresented its cybersecurity capabilities while experiencing a security breach in its BIG-IP product development environment.
  • The alleged misrepresentation occurred between August 9, 2025 (date of breach discovery) and September 2025 (end of touted 'best-in-class' security offerings).
  • The lawsuit pertains to shareholders who purchased FFIV stock prior to October 28, 2024.

The big picture

The lawsuit highlights the growing risk of legal action against companies that overstate their cybersecurity capabilities, particularly as cyberattacks become more sophisticated and frequent. This incident underscores the importance of transparent risk communication and robust internal controls, especially for companies whose products are integral to the security of other organizations. The timing of the alleged misrepresentation, coinciding with a known breach, raises serious questions about the integrity of F5's disclosures and the effectiveness of its oversight mechanisms.

What we're watching

Governance Dynamics
The outcome of the lawsuit will likely influence F5's board composition and oversight of cybersecurity risk management practices, potentially leading to increased scrutiny of executive compensation tied to security performance.
Regulatory Headwinds
This incident may accelerate regulatory pressure on cybersecurity disclosures, particularly for companies providing critical infrastructure or security solutions, potentially requiring more granular and frequent reporting.
Execution Risk
F5’s ability to restore investor confidence and demonstrate improved security practices will be critical; any further breaches or disclosures could significantly impact its valuation and market position.

Coupang Faces Shareholder Lawsuit Over Undisclosed Data Breach

Event summary

  • Kuehn Law, PLLC is investigating Coupang’s officers and directors for potential breach of fiduciary duties.
  • A federal securities lawsuit alleges Coupang failed to disclose inadequate cybersecurity protocols that allowed a former employee to access customer data for six months.
  • The alleged breach subjected Coupang to increased regulatory and legal risk, which was not reported to the SEC.
  • The lawsuit concerns stock purchased prior to August 6, 2025.

The big picture

This lawsuit highlights the escalating risks associated with cybersecurity in the e-commerce sector, where vast amounts of customer data are prime targets. The failure to promptly disclose a significant data breach can expose companies to substantial legal and financial liabilities, as well as erode investor confidence. The case underscores the increasing scrutiny of corporate governance practices related to data security and reporting obligations.

What we're watching

Regulatory Headwinds
The SEC's response to the alleged reporting failure will likely set a precedent for disclosure timelines regarding data breaches, potentially increasing compliance burdens for other e-commerce firms.
Governance Dynamics
The outcome of the lawsuit could trigger a reassessment of Coupang’s board oversight and executive compensation structures, particularly concerning cybersecurity risk management.
Execution Risk
The ongoing litigation and associated reputational damage may distract management and hinder Coupang’s ability to execute on its growth strategy, especially in competitive markets.

Integer Holdings Faces Securities Suit Over EP Market Claims

Event summary

  • Kuehn Law is investigating Integer Holdings Corporation (ITGR) officers and directors for potential breach of fiduciary duties.
  • A federal securities lawsuit alleges Integer misrepresented its competitive position in the EP manufacturing market.
  • The lawsuit claims Integer failed to disclose a sustained decline in sales for two EP devices despite claims of strong customer demand.
  • The alleged misrepresentations occurred on or before July 25, 2024, the cutoff date for potential investors to contact Kuehn Law.
  • Kuehn Law is covering all case costs for potential ITGR investors.

The big picture

This lawsuit highlights the risks associated with overly optimistic sales projections and the importance of transparent financial reporting, particularly in the competitive medical device sector. Integer's claims regarding its position in the EP market appear to have been challenged, potentially reflecting broader concerns about the sustainability of growth in this niche. The investigation underscores the increasing pressure on companies to accurately represent their performance and prospects to investors.

What we're watching

Financial Scrutiny
Increased scrutiny of Integer’s financial reporting and sales projections is likely, potentially impacting investor confidence and stock valuation.
Management Accountability
The outcome of the lawsuit will likely influence the board’s oversight of management and potentially lead to changes in executive compensation structures.
Market Perception
The lawsuit could damage Integer’s reputation within the EP manufacturing market, potentially affecting future customer relationships and market share.

iRhythm Technologies Faces Shareholder Lawsuit Over Zio AT Monitor Disclosure

Event summary

  • Kuehn Law, PLLC is investigating iRhythm Technologies (IRTC) officers and directors for potential breach of fiduciary duties.
  • The lawsuit alleges iRhythm insiders misrepresented the Zio AT monitor as a real-time device primarily for high-risk patients.
  • The alleged misrepresentation inflated the stock price, with the key date of concern being prior to November 5, 2021.
  • Kuehn Law is soliciting shareholders who purchased IRTC stock before November 5, 2021, to participate in the lawsuit.

The big picture

This lawsuit highlights the increasing scrutiny of medical device companies regarding product disclosures and their impact on investor expectations. The premium pricing associated with devices targeted at high-risk patients amplifies the potential for misrepresentation claims, and the case underscores the importance of transparent communication with investors, particularly in a market increasingly sensitive to governance and compliance risks. The timing of the alleged misrepresentation, prior to November 2021, suggests a potential window of vulnerability that could have affected a significant number of investors.

What we're watching

Litigation Outcome
The resolution of this lawsuit will significantly impact iRhythm's reputation and potentially lead to financial penalties and management changes, influencing investor confidence.
Regulatory Scrutiny
The allegations regarding the Zio AT monitor's intended use may trigger increased scrutiny from regulatory bodies like the FDA, potentially impacting future product approvals and marketing practices.
Disclosure Practices
iRhythm will likely face pressure to enhance its disclosure practices regarding product capabilities and target patient populations, which could affect future investor relations and financial reporting.
CID: 2880